其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Verteporfin CAS Registry Number: 129497-78-5 维替泊芬

CAS Name: (4R,4aS)-rel-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester
Additional Names: BPD-MATrademarks...
Literature References: Benzoporphyrin photosensitizer. Preparative method: A. M. Richter et al., J. Natl. Cancer Inst. 79, 1327 (1987). Photosensitizing efficiency: A. M. Richter et al., Biochem. Pharmacol. 43, 2349 (1992). Spectral characterization: R. Gillies et al., J. Photochem. Photobiol. B 33, 87 (1996). Tissue uptake parameters: R. K. Chowdhary et al., Biopharm. Drug Dispos. 19, 395 (1998). Clinical trial in macular degeneration: TAP Study Group, Arch. Ophthalmol. 117, 1329 (1999). Review of pharmacology and clinical experience: K. J. Mellish, S. B. Brown, Expert Opin. Pharmacother. 2, 351-361 (2001); S. J. Bakri, P. K. Kaiser, ibid. 5, 195-203 (2004).

Semotiadil CAS Registry Number: 116476-13-2 司莫地尔

CAS Name: (2R)-2-[2-[3-[[2-(1,3-Benzodioxol-5-yloxy)ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl-2H-1,4-benzothiazin-3(4H)-one
Additional Names: (+)-(R)-3,4-dihydro-2-[5-methoxy-2-[3-[N...
Literature References: Benzothiazine calcium antagonist. Prepn: J. Iwao et al., WO 8700838; eidem, US 4786635 (1987, 1988 both to Santen). Synthesis: M. Fujita et al., J. Med. Chem. 33, 1898 (1990). LC determn in plasma: K. Morishima et al., J. Chromatogr. 527, 381 (1990). Molecular conformation and crystal structure: A. Ota et al., Chem. Pharm. Bull. 41, 1681 (1993). Electrophysiology: N. Miyawaki et al., J. Cardiovasc. Pharmacol. 16, 769 (1990); and antiarrhythmic effects: eidem, Drug Dev. Res. 22, 293 (1991). Antihypertensive effects in rats: A. Kanda, H. Hashimoto, Jpn. J. Pharmacol. 63, 121 (1993). Mechanism of action study: K. Murakami et al., J. Cardiovasc. Pharmacol. 25, 262 (1995).

Butenafine CAS Registry Number: 101828-21-1 布替萘芬

CAS Name: N-[[4-(1,1-Dimethylethyl)phenyl]methyl]-N-methyl-1-naphthalenemethanamine
Additional Names: N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine
Percent Composition: C 87.01%, ...
Literature References: Benzylamine antifungal; squalene epoxidase inhibitor. Prepn: T. Maeda et al., EP 164697; eidem, US 5021458 (1985, 1991 both to Kaken). Antifungal activity in vivo: T. Arika et al., Antimicrob. Agents Chemother. 34, 2250 (1990). Review of antifungal activity, mechanism of action, and clinical trials: R. Fukushiro et al., in Recent Progress in Antifungal Chemotherapy, H. Yamaguchi et al., Eds. (Dekker, New York, 1992) pp. 147-157. Clinical trial in treatment of athlete's foot: T. A. Syed et al., Clin. Drug Invest. 9, 393 (2000).

Doxacurium Chloride CAS Registry Number: 106819-53-8 多库酯钠

CAS Name: (1R,1'S,2S,2'R)-rel-2,2'-[(1,4-Dioxo-1,4-butanediyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]isoquinolinium] dichloride...
Literature References: Benzylisoquinolinium, competitive neuromuscular blocker. Prepn: H. A. El-Sayad et al., EP 54309 (1982 to Wellcome Found.); eidem, US 4701460 (1987 to Burroughs Wellcome). Clinical pharmacology: S. J. Basta et al., Anesthesiology 69, 478 (1988). Clinical evaluation during anesthesia: R. P. F. Scott, J. Norman, Br. J. Anaesth. 62, 373 (1989).

Atracurium Besylate CAS Registry Number: 64228-81-5 苯磺酸阿曲库铵

CAS Name: 2,2'-[1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] dibenzenesulfonate
Additional Names: ...
Literature References: Benzylisoquinolinium, competitive neuromuscular blocker. Prepn: J. B. Stenlake et al., DE 2655883; eidem, US 4179507 (1977, 1979 both to Burroughs Wellcome). Pharmacology: R. Hughes, D. J. Chapple, Br. J. Anaesth. 53, 31 (1981). Clinical pharmacology: S. J. Basta et al., Anesth. Analg. 61, 723 (1982). Neuromuscular effects in man: R. L. Katz et al., ibid. 730. Metabolic studies: E. A. Neill, D. J. Chapple, Xenobiotica 12, 203 (1982). Pharmacokinetics: S. Ward et al., Br. J. Anaesth. 55, 113 (1983). Use during halothane anesthesia in humans: J. A. Stirt et al., Anesth. Analg. 62, 207 (1983). Symposium on pharmacology, metabolism, and clinical studies: Br. J. Anaesth. 55, Suppl. 1, 1S-139S (1983); on pharmacokinetics and clinical experience: ibid. 58, Suppl. 1, 1S-113S (1986).

Phalloidin CAS Registry Number: 17466-45-4 鬼笔环肽

Additional Names: Phalloidine
Percent Composition: C 53.29%, H 6.13%, N 14.20%, O 22.31%, S 4.06%
Literature References: Best known of the toxins isolated from the poisonous green fungus Amanita phalloides (Fr.) Seer., Agaricaceae, known as "the green death cap" or "deadly agaric": Lynen, Wieland, Ann. 533, 93 (1938). Structure: Wieland, Schön, ibid. 593, 157 (1955); Wieland, Schöpf, ibid. 626, 174 (1959); Wieland, Schnabel, ibid. 657, 225 (1962). Differs from amanitin in rapidity of action; at high dose levels, death of mice or rats occurs within 1 or 2 hours. Phalloidin acts by binding actin, q.v., an essential internal structural protein. Ultrastructural pathology: M. A. Russo et al., Am. J. Pathol. 109, 133 (1982). Toxicity study: Vogt, Arch. Exp. Pathol. Pharmakol. 190, 406 (1938). Review of the chemistry and toxicology of the toxins of Amanita phalloides: Wieland, Wieland, Pharmacol. Rev. 11, 87-107 (1959); see also T. Wieland, Fortschr. Chem. Org. Naturst. 25, 214-250 (1967); T. Wieland, H. Faulstich, Crit. Rev. Biochem. 5, 185-260 (1978).

D -Glucaric Acid CAS Registry Number: 87-73-0 葡萄糖二酸

Additional Names: Saccharic acid; D-glucosaccharic acid; D-tetrahydroxyadipic acid
Percent Composition: C 34.29%, H 4.80%, O 60.91%
Literature References: Best prepd by nitric acid oxidation of starch; yields as high as 65% are obtained in contrast to much lower yields from glucose or sucrose: Kiliani, Ber. 58, 2344 (1925); Schmidt et al., ibid. 70, 2402 (1937). Prepn from D-glucose: Mehltretter et al., US 2472168 (1949 to U.S. Secy. Agr.); Truchan, US 2809989 (1957 to Cowles Chem.); Phillips et al., J. Chem. Soc. 1958, 3522; BE 615023 (1962 to Ciba).

Potassium Sulfide CAS Registry Number: 1312-73-8 无水硫化钾

Additional Names: Potassium monosulfide
Percent Composition: K 70.92%, S 29.08%
Literature References: Best prepd from the elements in liq ammonia: Klemm et al., Z. Anorg. Allg. Chem. 241, 281 (1939); Feher in Handbook of Preparative Inorganic Chemistry vol. 1, G. Brauer, Ed. (Academic Press, New York, 2nd ed., 1963) pp 360-361.

Nopol CAS Registry Number: 35836-73-8; 128-50-7 ((±)-form) 6,6-二甲基联环(3.1.1)庚烷-2-烯-2-乙醇

CAS Name: (1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-ene-2-ethanol
Percent Composition: C 79.46%, H 10.91%, O 9.62%
Literature References: Bicyclic primary alcohol found in carrot root oil; synthesized from b-pinene, q.v. Prepn: J. P. Bain, J. Am. Chem. Soc. 68, 638 (1946). Thermal isomerization: idem et al., ibid. 74, 4292 (1952). Isoln from carrot root oil: D. M. Alabran et al., J. Agric. Food Chem. 23, 229 (1975). Applications as a polymer substrate: J. V. Crivello, S. S. Liu, J. Polym. Sci. A 37, 1199 (1999). Improved syntheses: U. R. Pillai, E. Sahle-Demessie, Chem. Commun. 2004, 826; A. L. Villa de P et al., Catal. Today 107-108, 942 (2005).

Bendamustine CAS Registry Number: 16506-27-7 宾达氮芥

CAS Name: 5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid
Additional Names: g-[1-methyl-5-[bis(b-chloroethyl)amino]-2-benzimidazolyl]butyric acid
Percent Composition: C...
Literature References: Bifunctional alkylating agent. Prepn: W. Ozegowski, D. Krebs, J. Prakt. Chem. 20, 178 (1963); eidem, Zentralbl. Pharm. Pharmakother. Laboratoriumsdiagn. 110, 1013 (1971). Antitumor activity: W. Jungstand et al., ibid. 1021. Capillary GC determn in plasma: H. Weber et al., J. Chromatogr. 525, 459 (1990). Toxicity study: U. Horn et al., Arch. Toxicol. Suppl. 8, 504 (1985). Clinical evaluation in non-Hodgkin's lymphomas: K. Bremer, J. Cancer Res. Clin. Oncol. 128, 603 (2002); in chronic lymphocytic leukemia: T. Lissitchkov et al., ibid. 132, 99 (2006); with prednisone in multiple myeloma: W. Pönisch et al., ibid 205. Review of pharmacology and clinical development: K. Bremer, W. Roth, Tumordiagn. Ther. 17, 1-6 (1996); J. A. Barman Balfour, K. L. Goa, Drugs 61, 631-638 (2001).